1.12
-0.88%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biostem Technologies
Its shares trade under the ticker BSEM. It has been listed since 11 July 2001. In the fiscal year to 31 December 2024, it reported revenue of $301.8m and net income of $31.9m. At that date it held total assets of $140.4m and shareholders' equity of $40.9m.
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is a biotechnology company focused on the development of anti-aging nutraceutical and cosmeceutical products, stem cell therapies, pharmaceuticals and educational provider of cell treatment protocols. The firm's divisions include Biostem Cell Therapy, Biostem Pharmaceuticals and Biostem Wellness. Biostem Cell Therapy provides stem cell therapies, stem cell banking, stem cell therapy, and stem cell research and development. Biostem Pharmaceuticals provides research and product development, active pharmaceutical ingredient (API) re-packaging and lab services. Biostem Wellness provides anti-aging and rejuvenation products and services, wellness and management programs, among others. The firm's subsidiaries include Biostem Wellness, Inc., Biostem Pharmaceuticals, Inc., Biostem Cell Therapy, Inc., Biostem International Inc. and Biostem Helps, Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Jul 2001
- Employees
- 67
- Website
- biostemtechnologies.com ↗
- Head office
- 2836 CENTER PORT CIRCLE, POMPANO BEACH, FL, 33604
- Incorporated in
- FL
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Thomas DuganIndependent Non-Executive Chairman of the Board$60,000
- Mr. Jason MatuszewskiChief Executive Officer, Director, since 2018$275,000
- Mr. Brandon PoeChief Financial Officer, Director, since 2022$60,000
- Mr. Andrew Van VurstChief Operating Officer, Director, since 2016$275,000
- Mr. Michael FortunatoChief Accounting Officer$455,000
- Mr. Shawn MccarreyChief Commercial Officer
- Mr. Patrick DalyIndependent Director$60,000
- Mr. Kenneth WarringtonIndependent Director$45,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biostem Technologies Inc has a strong portfolio of intellectual property rights, including patents and trademarks, which provide a competitive advantage in the stem cell technology sector.
- The company has a highly skilled and experienced management team with a deep understanding of the biotech industry.
- Biostem Technologies Inc has established strategic partnerships with leading research institutions and healthcare organizations, enabling access to cutting-edge technology and expertise.
- The company has a strong financial position, with a stable cash flow and a solid balance sheet.
Weaknesses
- Biostem Technologies Inc faces regulatory challenges and potential legal constraints due to the evolving nature of stem cell research and therapy.
- The company is heavily dependent on successful clinical trials and regulatory approvals, which can be a lengthy and costly process.
- Biostem Technologies Inc operates in a highly competitive market with other established players, which creates pricing pressure and market saturation risks.
Opportunities
- The increasing demand for personalized medicine and regenerative therapies presents a significant growth opportunity for Biostem Technologies Inc.
- Advancements in technology and research open doors for the development of innovative treatment options, allowing the company to expand its product portfolio.
- Expanding into new geographic markets with less stringent regulations can provide Biostem Technologies Inc with an opportunity to gain a competitive edge.
Threats
- The potential for negative public perception and ethical controversies surrounding stem cell research poses reputational risks for Biostem Technologies Inc.
- Changes in government regulations or policies related to stem cell research and therapy can significantly impact the company's operations and profitability.
- Intense competition in the biotechnology industry and the emergence of new technologies could pose challenges to Biostem Technologies Inc's market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.